ReviewInternational journal of molecular sciences2025
Sprouty in Tumors of the Nervous System.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Sprouty (SPRY) proteins are evolutionarily conserved modulators of growth factor-induced signaling pathways. The four different SPRY isoforms (SPRY1-4) are implicated in different types of cancer, acting as oncogenes or tumor suppressors depending on the SPRY isoform and the malignancy. Despite being tumor suppressors in many types of cancer, SPRY1 is an oncogene in rhabdomyosarcoma, SPRY2 in colorectal cancer, and SPRY4 in gastric cancer. In this review, we summarize the current literature about the functions of SPRY1-4 in glioblastoma (GB) and neuroblastoma (NB). To further delineate the effects of SPRY1-4 in the tumorigenesis of the nervous system, we analyzed the association of SPRY1-4 with the overall and event/progression-free survival of patients with pediatric and adult glioma, GB, and NB using public datasets. Together, there is evidence that SPRY1 and -2 are oncogenes in GB, whereas the role of SPRY3 and -4 in GB is not well defined. In NB, SPRY2 acts as a tumor suppressor, whereas the effects of SPRY1, -3, and -4 in NB have not been investigated so far, although the survival analysis revealed increased survival of NB patients with low SPRY3 levels in different datasets. Thus, this review demonstrates the requirement for further studies about the functions of the SPRY proteins in tumors of the nervous system to define their clinical relevance as potential therapeutic targets in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.